In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Recent technological advancements have enabled the profiling of a large number of genome-wide
features in individual cells. However, single-cell data present unique challenges that …

Several determinants of aging, including metabolic capacity and genetic stability, are
recognized in both yeast and humans. However, many aspects of the pathways leading to cell …

Gaining a better understanding of the immune cell subsets and molecular factors associated
with protective or pathological immunity against severe acute respiratory syndrome …

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb)
VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will …

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …